In Lilly’s partnership with Harvard Pilgrim Health Care, the not-for-profit insurer gets additional rebates if fewer patients using Lilly's diabetes treatment Trulicity meet blood sugar goals than expected.
Merck & Co. on Tuesday announced that it will end a study of its once-promising Alzheimer’s disease drug in patients with mild-to-moderate forms of the condition, just three months after Eli Lilly and Co. announced its own setback in a field that’s been littered with failures.
Two local men who have been working on a potential blockbuster treatment for a rare and debilitating disease are hopeful that a major injection of venture capital will provide the boost needed to move the drug to market—even if it means sweeping changes for their company.
One of the bill’s author said it is designed to help parents who are “up against a wall,” and he stressed that it should not be confused as a first step to medical marijuana legalization in the state.
Teva Pharmaceuticals Industries Ltd.’s proposed generic version infringes a patent on the multi-billion-dollar patent, the U.S. Court of Appeals for the Federal Circuit ruled.
A small Carmel-based biotech firm has signed a deal with international drug company Allergan Plc that is worth at least $50 million and could grow to more than $2 billion under the best-case scenario.
The executive director at White River State Park is fighting her way back from a ruptured brain aneurysm, a condition that leaves many of its victims disabled, or worse.
The company’s announcement reassured investors in the wake of last month’s news that the Alzheimer’s drug solanezumab had failed to demonstrate effectiveness during a large-scale clinical trial.
The point of chemo is to cure me. But these are not gentle chemicals. They sweep through my body like a tornado, with side effects that range from annoying to horrendous. But I have no choice.
The gift is the largest to the IU School of Medicine by an alumnus. The medical school will use the money to establish the Brown Center for Immunotherapy to fight some of the world’s toughest diseases.
The Indianapolis-based company, which last month struck out in a late-stage clinical trial for a potential Alzheimer’s drug called solanezumab, announced Friday a collaboration with AstraZeneca to develop another possible treatment for the mind-robbing disease.
In a few days, a new type of knockoff medicine will upend a $10 billion diabetes-drug market and exacerbate a brutal price war between some of its biggest players.
The FDA says the Indianapolis-based drugmaker and its partner can make an important label claim on its new diabetes drug—a move analysts say could give sales a big boost.
The company has requested a tax break from Indianapolis officials on the project that would save it about $484,000 over eight years.
With drug companies under fire, the world’s largest insulin maker plans to limit price increases and introducing a model that ties the cost of medicines to the results they deliver.
Eli Lilly and Co. plans to lay off hundreds of U.S. sales representatives in coming months, following the disappointing failure of an experimental drug for Alzheimer’s disease announced last week.
Analysts are all over the map on how investors should react to the Indianapolis-based drugmaker’s news that a promising drug failed to help patients.
Investors pummeled Eli Lilly and Co.’s stock Wednesday on the news that its experimental drug for Alzheimer’s disease failed to help patients, but a chorus of pharmaceutical analysts say they weren’t shocked by the setback.
Lartruvo is the first front-line therapy approved by the FDA to treat soft tissue sarcomas since doxorubicin more than 40 years ago.
Research developed at Purdue University and licensed by a biomedical startup could give patients with late-stage prostate cancer an alternative to hormone therapies that can develop resistance after prolonged use.
